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Abstract
In patients with haemophilia, regular replacement therapy with clotting factor concentrates (prophylaxis) is 
effective in preventing recurrent bleeding episodes into joints and muscles. However, despite this success, 
intra-articular and intramuscular bleeding is still a major clinical manifestation of the disease. Bleeding most 
commonly occurs in the knees, elbows, and ankles, and is often evident from early childhood. The pathogenesis 
of haemophilic arthropathy is multifactorial, with changes occurring in the synovium, bone, cartilage, and 
blood vessels. Recurrent joint bleeding causes synovial proliferation and infl ammation (haemophilic synovitis) 
that contribute to end-stage degeneration (haemophilic arthropathy); with pain and limitation of motion severely 
affecting patients’ quality of life. If joint bleeding is not treated adequately, it tends to recur, resulting in a vicious 
cycle that must be broken to prevent the development of chronic synovitis and degenerative arthritis. Effective 
prevention and management of haemophilic arthropathy includes the use of early, aggressive prophylaxis with 
factor replacement therapies, as well as elective procedures, including restorative physical therapy, analgesia, 
aspiration, synovectomy, and orthopaedic surgery. Optimal treatment of patients with haemophilia requires 
a multidisciplinary team comprising a haematologist, physiotherapist, orthopaedic practitioner, rehabilitation 
physician, occupational therapist, psychologist, social workers, and nurses. 
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Introduction
Haemophilia is an X-linked heritable coagulo pathy 
with an overall prevalence of approximately 1 in 10,000 
individuals [1]. The most common form is factor VIII 
defi ciency, or haemophilia A, which comprises approxi-
mately 80% of cases. Factor IX defi ciency, or haemophilia 
B, comprises approximately 20% of cases [2]. Other 
heritable clotting disorders include von Willebrand dis-
ease and various other clotting factor defi ciencies, but 
these are not commonly classifi ed as ‘haemophilia’ [3]. 
Haemophilia is traditionally classifi ed as ‘mild’, ‘mod-
erate’, or ‘severe’, depending on the degree of clotting 
factor defi cit compared with that found in the general 
population (Table 1) [4].
Phenotypically, patients with haemophilia are at risk of 
haemarthrosis (particularly of the knee, ankle, and elbow 
joints), soft-tissue haematomas, bruising, retroperitoneal 
bleeding, intracerebral haemorrhage, and post-surgical 
bleeding [5]. Generally speaking, individuals with ‘severe’ 
disease display clinical symptoms more frequently, and are 
considered at higher risk of haemorrhagic events and mus-
culoskeletal problems, although this is not always the case [4]. 
Treatment for haemophilia is frequently prophylactic (par-
ticularly in moderate or severe disease) and aims to reduce 
the frequency and severity of bleeds. In addition, treatment 
needs to be given if the patient has, or suspects they have, 
a bleed. Replacement therapy uses intravenous infusions of 
the defi cit clotting factor to reduce the risk of bleeding, and 
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patients may receive this at regular intervals (‘prophylactic 
therapy’) or in response to an acute bleeding episode (‘on-
demand therapy’) [6]. It should be mentioned that due to 
cost and lack of specialized care, access to replacement ther-
apy is, to a large extent, limited to developed countries only. 
In these countries, children now grow up with a relatively 
good musculoskeletal status, but this is not yet the case for 
the majority of patients who live in developing countries 
and resource-limited settings. Other agents that may be 
used in the treatment of a bleed include antifi brinolytics 
(used in both haemophilia A and B) and the synthetic vaso-
pressin analogue desmopressin (only in mild haemophilia A) 
[7]. Patients are advised to avoid drugs that affect platelet 
function (although they can be used in some cases), and to 
avoid trauma/contact sports (although low-impact exercise, 
such as cycling, is recommended to protect joints) [8].
The management of patients with haemophilia is com-
plex as their condition is associated with a large number 
of comorbidities. Joint problems resulting from recurrent 
haemarthrosis, such as chronic synovitis and degenerative 
arthritis, are a major cause of morbidity [9, 10]. Repeated 
bleeding into joints can result in abnormalities in both bone 
growth and limb length [5]. Patients are also at increased 
risk of developing osteoporosis as a result of prolonged 
periods of immobility and reduced range of joint move-
ment as a result of arthropathies [11]. Renal haemorrhage 
and haematuria are also cause for concern, and thromboses 
resulting from the use of antifi brinolytics may cause renal 
obstruction. Medications used for other comorbidities, such 
as blood-borne viral infections, are frequently nephrotoxic 
and hepatotoxic [5, 12]. Many patients with haemophilia, 
particularly those transfused before the introduction of 
virus-safe concentrates, were infected with hepatitis B, C, 
and HIV. These transfusion-acquired infections increase 
the risk of end-stage liver disease and cirrhosis, which in 
turn, increase the risk for hepatocellular carcinoma [13]. 
While a direct link between haemophilia and cancer is 
contentious, diagnosis and treatment of malignancy are 
problematic in these patients [14].
Replacement of missing clotting factors represents an 
effective method of treatment for patients with haemo-
philia; however, 20–30% of patients with haemophilia A 
and 5% of patients with haemophilia B develop inhibitory 
antibodies to factor VIII and factor IX, respectively, which 
drastically reduce the effi cacy of replacement therapy 
[15]. This represents a serious complication of treatment, 
which results in poorer prognosis, reduced quality of life, 
and increased cost of treatment [16].
Over time, complications from recurrent haemarthrosis 
and soft-tissue haematomas can result in severe arthropathy, 
joint contractures, and pseudotumours, leading to chronic 
pain and disability and impairment of health-related qual-
ity of life. Arthropathy as a consequence of haemophilia 
represents the single largest cause of morbidity in patients 
with haemophilia, and as such, prevention of this is one of 
the main aims of treatment [5, 17].
Despite these extensive comorbidities, with appropri-
ate treatment, patients with haemophilia can expect a 
near-normal life expectancy and an excellent health-
related quality of life [18–21]. The effectiveness of 
treatments means that increasingly, patients with hae-
mophilia are experiencing more of the health concerns 
associated with advancing age in the general population, 
such as cardiovascular disease, cancer, and declining 
renal function [19, 20, 22, 23]. Owing to the increasing 
age and number of older people living with haemo-
philia, the incidence of comorbidity and consequently 
high-risk patients is also increasing, and as survival of 
patients with haemophilia continues to improve, the 
impact of comorbidity and how best to manage it will 
become more important [19, 20, 24]. The presence of 
haemophilia and comorbidity raises important issues 
with regard to clinical decision-making and treatment 
decisions, and currently there is very little guidance for 
physicians to manage chronic comorbidity. This article 
reviews comorbid joint disease in haemophilia and how 
to manage it.
Haemophilia and joint disease: background
Joint disease is a disabling and common complication of 
severe (and, to a lesser extent, moderate) haemophilia, in 
which a characteristic chronic arthropathy develops as a 
result of recurrent bleeding into joints. Individuals with 
severe haemophilia are more likely to develop joint prob-
lems and reduced range of movement (ROM) of joints 
[25]. Other risk factors for developing ROM limitations 
include age and increased body mass index [25]. In those 
Table 1 Classifi cation of haemophilia. Adapted from [4, 7].
Factor level (IU/mL) Classifi cation Predisposition to bleeding Haemarthrosis
>0.05 to 0.40
 (>5 to 40% of normal)
Mild With severe injury, surgery Rarely
0.01 to 0.05
 (1–5% of normal)
Moderate With slight injury Sometimes
<0.01
 (<1% of normal)
Severe Spontaneous, with little or 
no trauma
Very frequently
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with severe disease, higher frequency of bleeds, presence 
of inhibitors, and recent orthopaedic procedures are also 
associated with increased likelihood of ROM limitation 
[25]. Data from the Universal Data Collection (UDC; 
US national public health surveillance project) showed 
that patients with severe haemophilia were more at risk 
of developing a target joint (a joint in which recurrent 
bleeding has occurred four or more times in the past 6 
months) than those with moderate or mild haemophilia 
(33.1% versus 18.8% and 5%, respectively) [26]. 
The most commonly affected joints in patients not 
treated with prophylaxis are the knees (45%), followed by 
the elbows (30%), ankles (15%), shoulders (3%), and wrists 
(2%) [8]. Today, at least in patients on prophylaxis, this pat-
tern appears to have changed, and the ankle joint now 
accounts for the most common site of bleeding [27]. This 
may be due to the fact that current prophylactic regimens 
and treatment in the home allow patients to be more active 
and able to participate in higher impact sports and activi-
ties, which could render the ankle the most vulnerable 
joint [27]. In individuals with severe haemophilia, the fi rst 
occurrence of haemarthrosis ordinarily occurs by around 
the age of 2 years [8]. If not treated adequately, these indi-
viduals will develop haemophilic arthropathy by the age of 
20 years [28]. An acute bleed into a joint results in severe 
pain as the pressure in the synovial cavity and bone marrow 
rises, and may lead to avascular osteonecrosis (particularly 
in the femoral head following a bleed into the hip joint) 
[5]. Recurrent bleeding leads to chronic synovitis and dam-
age to both cartilage and bone, in addition to the synovial 
damage [8]. If patients with severe disease do not receive 
appropriate treatment, they will develop clinical symptoms: 
pain, swelling, and reduced ROM by early adolescence that 
will severely affect their health and quality of life [21, 28]. 
Haemophilia and joint disease: pathophysiology
The development of haemophilic arthritis occurs in 
three stages [29]:
Acute haemarthrosis1. 
Chronic synovitis2. 
Degenerative arthritis.3. 
While the synovium lining a joint has a limited capac-
ity for absorbing blood following an isolated incident of 
haemarthrosis, recurrent bleeding into the joint results 
in a level of blood breakdown products that the synovial 
membrane cannot remove. Iron, a key constituent of hae-
moglobin found in erythrocytes, is thought to play a major 
part in infl aming the synovium [29]. The presence of the 
iron-rich breakdown product haemosiderin is thought 
to promote the production of pro-infl ammatory cyto-
kines such as interleukin (IL)-1, IL-6, and tumour necrosis 
factor-alpha [30, 31], and the induction of genes that causes 
Haemorrhage
Synovial
impingement
Synovial
hypertrophy
Enzymatic degradation
End stage
arthropathy
Direct synovial invasion
Synovial
inflammation
Recurrent
haemarthroses
Figure 1 A chronic, self-perpetuating cycle of haemarthrosis–
synovitis–haemarthrosis [29]. Reproduced with permission. © World 
Federation of Hemophilia, 2004.
cellular proliferation such as mdm2 [32] that result in the 
changes seen in synovial tissue in haemophilic synovitis. 
The synovium becomes increasingly vascular and hyper-
trophic, and infl ammatory cells are recruited to the area 
in greater numbers. This vascular and hypertrophied tissue 
is more likely to become impinged between the articular 
surfaces of the joint, resulting in increased likelihood of 
further haemarthrosis that creates a vicious cycle of bleed-
ing and infl ammation (Figure 1) [29, 33]. Furthermore, 
the infl ammatory mediators released interfere with the 
normal maintenance of articular cartilage. Damage to the 
articular cartilage is thought to occur both through direct 
exposure of the cartilage to blood and through synovium-
associated infl ammation [34, 35], and it has been shown 
that the exposure of cartilage to blood, even in the short 
term, leads to prolonged cartilage damage [33, 34]. The 
marked infl ammation and synovial hypertrophy noted in 
haemophilic arthropathy bear resemblance to the patho-
logical mechanisms seen in rheumatoid arthritis, while the 
progressive degeneration of the hyaline cartilage mimics 
that observed in osteoarthritis. These processes occurring 
in parallel result in a degenerative arthritis that progresses 
until the joint is completely destroyed [33, 36]. 
Haemophilia and joint disease: evaluation
Clinical evaluation of the joints, gait, motion, muscle 
tone, functional level of disability, pain and swelling 
must be performed to assist in the diagnosis of chronic 
synovitis and to guide treatment decisions. Tradition-
ally, clinical examination and plain fi lm radiography 
have been used to diagnose haemophilic arthropathy. 
Radiographs adequately demonstrate advanced bone 
changes such as epiphyseal overgrowth, joint space nar-
rowing, and osteoporosis, but have poor sensitivity in 
demonstrating early soft-tissue changes that occur before 
irreversible cartilage damage [17, 37, 38]. 
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Other imaging methods may be more useful in detect-
ing early soft-tissue changes. Magnetic resonance imaging 
(MRI) is currently the gold standard for diagnosing haemo-
philic arthropathy and is particularly useful for identifying 
soft-tissue changes [39]. MRI can accurately detect syno-
vial hypertrophy and joint effusions, which are common 
fi ndings at all stages of joint disease. A recent prospective 
study showed that MRI was more sensitive than radiog-
raphy in detecting joint abnormalities in boys with severe 
haemophilia A [17]. However, MRI is often limited owing 
to high costs, cumbersome use, requirement for sedation in 
children, and inability to differentiate active versus inactive 
synovium [38, 40]. Modalities such as contrast ultrasono-
graphy may be useful for visualizing synovial changes. 
The advantages of ultrasonography are that it is simple, 
inexpensive, convenient, and radiation-free [41–43]. 
Several scoring systems, including clinical and imag-
ing, have been developed to assess haemophilic joints. 
The World Federation of Hemophilia (WFH) scoring 
system, described by Gilbert [44], is based on the clini-
cal evaluation of the six index joints to assess several key 
parameters of severe haemophilic arthropathy. However, 
various shortcomings, including lack of established reli-
ability, validity, and sensitivity to smaller changes in patients 
with less severe joint disease, means that various modifi ca-
tions have been introduced. The current modifi ed clinical 
system is the Haemophilia Joint Health Score (HJHS) 
(Table 2) [45]. The Pettersson score [46] and the European 
MRI scale [47] are imaging techniques that derive the 
fi nal score from the sum of scores for individually rated 
features. The Arnold–Hilgartner score [48] and the Den-
ver MRI scale [49] produce radiological scores based on 
the most severe changes present. The international MRI 
subgroup has developed a consensus scoring system aimed 
at facilitating international comparisons between MRI 
data on haemophilic arthropathy [50]. 
Haemophilia and joint disease: management
Management of bleeding
Optimal management of haemophilic joint disease requires 
early prevention and treatment of acute joint bleeds before 
the onset of degenerative disease [8, 17, 29, 51]. Early 
treatment of joint haemorrhages can be achieved with 
replacement clotting factor concentrates [5]. The level of 
clotting factor must be suffi ciently high and maintained 
long enough to stop bleeding and to prevent recurrence 
[52]. However, despite the success of factor replacement 
therapy, intra-articular bleeding is still a major clinical 
manifestation of the disease, particularly in those with 
severe haemophilia or inhibitors.
Early prophylaxis with factor concentrates in children 
can prevent not only joint bleeding but also improve joint 
outcomes, particularly in those with severe haemophilia [17, 
53–61]. Prophylaxis is recommended as the fi rst choice of 
treatment for severe haemophilia by the World Health Organ-
ization [57] and the WFH [8] and by many national scientifi c 
societies. The Medical and Scientifi c Advisory Council of 
the US National Hemophilia Foundation recently recom-
mended prophylaxis as the standard of care for patients of all 
ages with severe haemophilia [62]. There are currently four 
models of prophylaxis in haemophilia [see 63]:
Primary prophylaxis based on age: continuous, long-1. 
term treatment started before the age of 2 years and 
before any clinically evident joint bleeding (where 
continuous implies treating up to adulthood for 52 
weeks a year, with a minimum of 46 weeks a year)
Primary prophylaxis based on fi rst joint bleed: 2. 
continuous, long-term treatment started before the 
onset of joint damage, regardless of age
Secondary prophylaxis: continuous long-term 3. 
treatment that does not meet the criteria for primary 
prophylaxis
Short-term prophylaxis: short-term treatment in 4. 
anticipation of, and to treat, bleeding.
There is a general consensus that prophylaxis with fac-
tor concentrates from an early age is the best method for 
preventing and/or reducing the risk of joint bleeds and 
arthropathy [17, 59, 60, 61, 63, 64]. The optimal dose, 
schedule, and timing of prophylaxis remain unclear 
issues. For maximum benefi t, the target trough factor lev-
els should be >1% between dosing [62]. This can usually 
be achieved by giving 25–50 IU/kg of factor VIII three 
times a week or every other day [17], or 40–100 IU/kg of 
factor IX two to three times a week [62]. Dosing is based 
on the half-life of the factor concentrates, but should be 
individualized and increased in the case of bleeding [65]. 
A retrospective comparison of high- and intermediate-
dose regimens showed comparable long-term orthopaedic 
outcomes; the lower dose regimen resulted in a few more 
bleeds per year, but considerably less factor concentrate 
consumption [66]. Moreover, a tailored treatment strat-
egy is an option that may require less factor concentrate 
than ‘traditional’ prophylactic approaches [59].
When to stop primary prophylaxis remains unclear and 
is poorly studied. Findings from retrospective analyses of 
prophylaxis in patients with severe haemophilia suggest 
that some patients, such as those with no, or very few, 
joint bleeds, may be able to stop prophylaxis in adulthood 
and switch to on-demand therapy [67, 68]. Results from 
Denmark and the Netherlands showed that during 4 years 
of follow-up, one-third of young adult patients with severe 
haemophilia, who had been receiving prophylaxis during 
childhood, discontinued prophylaxis in early adulthood, 
while maintaining a low joint bleed frequency and similar 
arthropathy to those who continued prophylaxis [68].
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For patients with active chronic synovitis and fre-
quently recurring haemarthroses, short treatment 
courses (6–8 weeks) of secondary prophylaxis with 
intensive physiotherapy are recommended [8]. In cases 
where prophylaxis is not feasible or appropriate, on-
demand therapy should be given as early as possible at 
the onset of a bleeding episode [57]. 
Adjunctive management
Analgesics
Analgesics may be required for the relief of pain due 
to bleeding into the joint [52]. However, bleeding can 
be aggravated by analgesics, such as aspiring-containing 
compounds or other non-steroidal anti-infl ammatory 
drugs [8]. Safer alternatives include paracetamol/acet-
aminophen and milder opioid analgesics. 
Anti-infl ammatory treatment
When the acute haemarthrosis phase is over, consider-
ation must be given to the synovitis that often develops. 
Although non-steroidal anti-infl ammatory drugs have 
typically been contraindicated in the bleeding disorder 
population, each individual should be assessed for the 
appropriateness of this medication or the more modern 
variant of cyclo-oxygenase 2 inhibitors. Treatment with 
intra-articular corticosteroid injection has been described 
for chronic synovitis [69]. The role of systemic corti-
costeroids is limited due to their side-effects, but could 
be considered in specifi c cases of severe infl ammatory 
Table 2 Haemophilia Joint Health Score [45].
Left ankle Right ankle Left elbow Right elbow Left knee Right knee Other
Swelling
Duration (swelling)
Muscle atrophy
Axial alignment
Crepitus on motion
Flexion loss
Instability
Joint pain
Strength
Gait
Joint total
Global gait score
Total score (sum of joint totals + global gait score)
Swelling
 0 = no swelling
 1 = mild
 2 = moderate
 3 = severe
Duration 
 0 = no swelling or <6 months
 1 = >6 months
Muscle atrophy
 0 = none
 1 = mild
 2 = severe
Axial alignment
 Measured only at knee and ankle
 0 = within normal limits
 2 = outside normal limits
Flexion loss
 0 = <5
 1 = 5–10
 2 = >20
Extension loss
 0 = <5
 1 = 5–10
 2 = 11–20
 3 = >20
Instability 
 0 = none
 1 = signifi cant pathological joint laxity
Joint pain
 0 = no pain either through range or at end ROM
 1 = present (observed, grimace, withdrawal or resistance)
Strength (using Daniels and Worthington’s scale)
 Within available ROM
0 =  holds rest position against gravity with maximum resistance 
 (gr. 5)
1 =  holds test position against gravity with moderate resistance 
 (but breaks with maximal resistance) (gr. 4)
2 = holds test position with minimal resistance (gr. 3+), or holds test position against gravity (gr. 3)
3 =  able to partially complete ROM against gravity (gr. 3−/2+), or able to move through ROM gravity 
 eliminated (gr. 2), or through partial ROM gravity eliminated
4 = trace (gr. 1) or no muscle contraction (gr. 0)
gr., grade; ROM, range of motion.
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haemophilia and, except for selected cases, it is generally 
not recommended in consensus guidelines [70]. Aspira-
tion can be considered in certain circumstances, such 
as hip haemarthrosis and other major and painful hae-
marthroses, and should be performed early following a 
bleeding episode (<12 hours). Joint aspiration may also 
be considered in patients with acute haemarthrosis who 
do not respond to factor replacement therapy within 
48–72 hours and in cases where pain and swelling out-
weigh bleeding alone (a septic joint must be ruled out). 
Aspiration should be performed with adequate factor 
replacement (factor levels of at least 30–50% for 48–72 
hours) [8] and in aseptic conditions to avoid recurrence 
or septic arthritis [71]. Following aspiration, the joint 
should remain immobilized for at least 1 hour [8].
Surgical treatments
Open surgical procedures are often used for patients 
with severe joint impairments where conservative 
therapies have failed. The benefi ts of surgery must out-
weigh the potential risks, such as infection, neuropathy, 
and haemorrhage, particularly in patients with severe 
haemophilia and/or inhibitors. 
Synovectomy
For synovitis that is refractory to treatment, but not 
too hypertrophic and without severe cartilage dam-
age, synovectomy is recommended to prevent both the 
progression of haemophilic arthropathy and the devel-
opment of end-stage arthropathy [72]. Synovectomy 
does not remove the cause of the synovitis, so ongoing 
management of the underlying disease process infl u-
ences successful outcome. 
The fi rst step to treating synovitis refractory to medi-
cal treatment is the use of non-surgical synovectomies 
(synoviortheses), which involve the percutaneous injec-
tion of radioisotopes (yttrium, dysprosium, rhenium, or 
phosphorus) or chemical agents (rifampicin or oxytet-
racycline) to generate fi brosis of the hypertrophied 
synovium [29, 72]. These procedures are minimally 
invasive, suggested to temporarily preserve ROM, can 
be performed in the outpatient setting, do not require 
aggressive physical therapy, require minimal coverage 
with clotting factor concentrates, can be performed in 
patients with inhibitors, result in fewer haemorrhagic 
episodes, and are cheaper than surgical synovectomy 
[29, 72]. However, complications such as articular carti-
lage damage, infection, and no relief of symptoms may 
be associated with the procedure. In addition, two cases 
of leukaemia have been reported in patients receiving 
radiosynovectomy using phosphorus 32-sulphur col-
loid (P32) for haemophilic arthropathy, raising concerns 
reaction refractory to other treatments. The evidence 
for medical anti-infl ammatory treatment in this patient 
population was recently reviewed by Hermans et al. [70] 
and considered very low.
Rest, ice, compression, and elevation (RICE)
For patients with minor haemarthroses, immobilization may 
not be required. For other patients, RICE may be useful 
adjunctive management strategies for pain relief [8]. Ice packs 
can be applied for 20 minutes, every 4–6 hours, until pain 
relief. Support to the joint with splints, slings, or pressure 
bandages can also help to relieve pain. Rest for lower-limb 
bleeding episodes should include bed rest (1 day), eleva-
tion when sitting (3–4 days), avoidance of weight-bearing, 
and the use of crutches or a wheelchair when ambulating 
[8]. Immobilization of the painful joint should occur for as 
short a time as possible and for as long as necessary. However, 
long-term rest can result in limitation of motion and muscle 
atrophy [8, 52]. Joint rehabilitation is therefore critical to 
restore and/or maintain muscle strength and joint ROM. 
Physiotherapy
Physiotherapy is an important treatment modality to 
help preserve movement and function to the joints, to 
reduce swelling and pain, to maintain muscle strength, 
and to prevent injury. It is important that the physio-
therapist is educated about the unique physiology of the 
haemophilia patient, and makes clinical decisions based 
on valid research. 
Physiotherapy should be initiated as soon as the patient 
can tolerate it. For subacute haemarthroses, 6–8 weeks of 
physiotherapy is recommended [71]. Following each fac-
tor concentrate injection, the patient should undergo an 
exercise programme that focuses on active joint mobility, 
progressive strengthening, gait training, pain management, 
and self-physiotherapy at home [71]. The physiotherapist 
will design a specifi c course of exercises that are tailored 
to the individual patient. In cases of severe joint damage 
and surgery, physiotherapy is required for the rehabilita-
tion process. Preventive physiotherapy can be utilized to 
help strengthen the muscles surrounding the joints, and to 
improve mobility, fl exibility, and balance. A physiothera-
pist can also provide advice on adopting an appropriate 
lifestyle and undertaking physiotherapy to prevent and 
manage bleeds and other musculoskeletal problems [71]. 
Joint aspiration
Joint aspiration is a method for reducing the load of 
blood after a joint bleed [8]. It can help relieve pain and 
spasm and speed up rehabilitation [71]. However, there 
are very limited data on joint aspiration in patients with 
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Future perspectives
New products with improved pharmacokinetics, allowing 
for less frequent injections while maintaining therapeutic 
factor levels, may limit the use of central venous access 
devices, improve compliance, enable treatment to be 
initiated earlier, and therefore have the potential to pre-
serve joint function and prevent the onset of arthropathy 
in non-inhibitor patients. Those with already existing 
joint disease may instead benefi t from the general prog-
ress made in many of the medical areas; for example, 
blood-induced joint damage includes both infl amma-
tion-mediated mechanisms as well as cartilage-mediated 
processes. It has been suggested that IL-10, for example, 
might be used locally and could therefore modulate joint 
damage induced by haemarthroses [33].
Conclusions 
Prophylaxis by replacement of the missing factor in patients 
with haemophilia is the optimal way to prevent the occur-
rence of haemarthrosis and thereby the onset of arthropathy, 
provided that it is started early in life. Dosing should be 
individualized and increased in the case of bleeding. Pre-
vention of bleeding episodes through early treatment will 
prevent accumulation of blood in the joint and the subse-
quent infl ammation and potential haemophilic arthropathy. 
Treatment must be maintained until bleeding remission 
and patients have recovered as much of their ROM and 
muscular strength as possible. Clinical evaluation of the 
joints, gait, motion, muscle tone, functional level of disabil-
ity, pain, and swelling, as well as imaging techniques, must 
be performed to assist in the diagnosis of chronic synovitis 
and to guide treatment decisions. The fi rst step to treat-
ing synovitis, refractory to medical treatment, is the use of 
synovectomies, non-surgical or surgical interventions. In 
many cases, joint deformities have to be treated by open 
orthopaedic surgery. State-of-the-art treatment of patients 
with haemophilia requires a multidisciplinary team.
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about the safety of this procedure [73, 74]. Thus, the ben-
efi ts of radiosynovectomy need to be carefully weighed 
against the potential risks, with careful monitoring for 
long-term side-effects. 
Radiosynovectomy is generally more reliable and quicker 
at inactivating the synovium than chemical synovectomy 
[29, 72]. When available, radiosynovectomy is the treat-
ment of choice [29, 72]. Ideally, radiosynovectomy should 
be performed before irreversible joint destruction has 
occurred. In cases where radiosynovectomy is not available, 
chemical synovectomy with rifampicin is recommended. 
Treatment with up to three consecutive applications of 
radioisotope at 6-monthly intervals and up to seven appli-
cations of chemical agents at weekly intervals are thought 
to be appropriate before more invasive treatments are 
considered [72, 75]. 
Surgical synovectomy may be performed as an open 
surgical procedure or with the aid of arthroscopy, which 
avoids the need for large incisions, is associated with 
less frequent loss of motion, and allows for faster reha-
bilitation and a more thorough removal of synovial 
tissue [29, 72]. The procedure may be more effective 
in younger patients with radiologically less advanced 
joint arthropathy. However, arthroscopy is considerably 
more time-consuming than open surgery, and patients 
still require hospitalization, comprehensive physiother-
apy, and large amounts of clotting factor concentrates 
[29, 72]. 
Joint debridement
Joint debridement is minimally invasive surgery that 
removes synovitis and loose cartilage from the joint [76]. 
Arthroscopic joint debridement should be considered in 
young patients to prevent or delay the requirement for 
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